Kiniksa Pharmaceuticals Ltd (Kiniksa) is a biopharmaceutical company that discovers, acquires, develops and commercializes medicines to treat autoinflammatory and autoimmune diseases. The company's pipeline product portfolio includes Rilonacept drug for the treatment of recurrent pericarditis; mavrilimumab, against giant cell arteritis, COVID-19 and hyper inflammation; vixarelimab, targeting prurigo nodularis and diseases characterized by chronic pruritus; KPL-404, a monoclonal antibody to treat T-cell dependent, B-Cell–mediated indications. It develops medicines in the therapeutic areas of cardiovascular, dermatology and autoimmune diseases. The company operates in Bermuda, the US and the UK. Kiniksa is headquartered in Hamilton, Bermuda.
Headquarters
Bermuda
Address
Clarendon House, 2 Church Street, Hamilton, HM11
Website
www.kiniksa.com
Telephone
1 441 7814399100
No of Employees
297
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KNSA (NASD)
Revenue (2022)
$270.3M
22.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-92.3%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
-93.7%
(2022 vs 2021)
* As of and is in US$
Kiniksa Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Arcalyst |
| Rilonacept- Recurrent Pericarditis | |
| Mavrilimumab- Giant Cell Arteritis, COVID-19 and Chronic Inflammatory Disease | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Kiniksa Pharmaceuticals Ltd | AbbVie Inc | Sanofi | Novartis AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | Bermuda | United States of America | France | Switzerland | United States of America |
| City | Hamilton | North Chicago | Paris | Basel | Princeton |
| State/Province | - | Illinois | Ile-de-France | - | New Jersey |
| No. of Employees | 297 | 50,000 | 87,994 | 76,057 | 34,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sanj K. Patel | Chairman; Chief Executive Officer | Executive Board | 2015 | 53 |
| Mark Ragosa | Senior Vice President; Chief Financial Officer | Senior Management | 2021 | 49 |
| Eben Tessari | Senior Vice President; Chief Operating Officer | Senior Management | 2022 | 41 |
| Michael Megna | Chief Accounting Officer; Vice President - Finance | Senior Management | 2022 | 52 |
| Chad Morin | Vice President; Chief Compliance Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward